Roche Joins Race for Obesity Drugs With $2.7 Billion Carmot Deal
Roche agreed to take over unlisted obesity drug developer Carmot Therapeutics for $2.7 billion upfront, joining a list of contestants seeking to challenge the dominant makers of weight-loss drugs Novo Nordisk and Eli Lilly.
Reuters Health Information
source https://www.medscape.com/s/viewarticle/999015?src=rss
Reuters Health Information
source https://www.medscape.com/s/viewarticle/999015?src=rss
Comments
Post a Comment